Skip to content

Efficacy and safety of elobixibat in elderly patients with chronic constipation in clinical practice -Retrospective observation research-

Efficacy and safety of elobixibat in elderly patients with chronic constipation in clinical practice - Efficacy and safety of elobixibat in elderly patients with chronic constipation in clinical practice

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000037286
Enrollment
160
Registered
2019-07-05
Start date
2019-07-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic constipation

Interventions

None listed

Sponsors

Kunimoto Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with 65 years or older 2. Patients with chronic constipation who must include 2 or more the following 6 items a. Straining during more than one-fourth of defecations b. Lumpy or hard stools (BSFS 1or 2) more than one-fourth of defecations c. Sensation of incomplete evacuation more than one-fourth of defecations d.Sensation of anorectal obstruction/blockage more than one-fourth of defecations e. Manual maneuvers to facilitate more than one fourth of defecations f. Fewer than 3 spontaneous bowel movements per week 3. Patients who starts Elobixibat administration from April 19, 2018 to March 31, 2019 (including concomitant use with other constipation drugs)

Exclusion criteria

Exclusion criteria: 1. Patients who had a history of hypersensitivity of elobixibat 2. Patients who are confirmed or suspected intestinal obstruction due to tumor, hernia etc. 3. Patients who are suspected constipation due to organic disease 4. Patients whose physicians judged that administration of elobixibat was inappropriate

Design outcomes

Primary

MeasureTime frame
Comparison of CSS total score between baseline and at weeks 2 of administration

Secondary

MeasureTime frame
Comparison of CSS sub score sbetween baseline and at weeks 2 of administration Comparison of Bristol Stool Form Scale (BSFS) between baseline and at weeks 2 of administration etc.

Countries

Japan

Contacts

Public ContactAbe Tatsuya

Kunimoto Hospital Director

abetatsuya99@gmail.com0166-25-2241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026